Chart-Typ:
Zeitraum:
| Oruka Therapeutics, Inc.: Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer | MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard... ► Artikel lesen |
| Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen |
| Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer | Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations | QTORIN rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | First module of the rolling NDA for QTORIN rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing... ► Artikel lesen |
| Dianthus Therapeutics: Kurseinbruch nach C1-Rückschlag - warum der Bullen-Case jetzt an Stärke gewinnt | Dianthus Therapeutics hat nach einem Rückschlag im C1-Inhibitor-Programm für HAE einen massiven Kursrückgang verzeichnet, der die Bewertung deutlich unter das aus fundamentaler Sicht gerechtfertigte... ► Artikel lesen |
| Dianthus Therapeutics-Aktie: Das Zeug zum großen Biotech-Gewinner | Die Aktie von Dianthus Therapeutics bietet Anlegern eine interessante Kombination aus hoher Liquidität, einer fortgeschrittenen Pipeline und dem Potenzial für eine breitere neuromuskuläre Plattform.... ► Artikel lesen |
| Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results | Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THESEUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.